5 completed, 4 recruiting, 2 active not recruiting, 2 not yet recruiting. 16 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 5, Recruiting 4, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2, Enrolling by invitation 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
Follow Duchenne Muscular Dystrophy (DMD): new trials by email Literature Review of Duchenne Muscular Dystrophy (DMD) trials Research Report on Duchenne Muscular Dystrophy (DMD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 30 | 2026-12-01 | 2026-11-12 |
| A Trial to Investigate the Efficacy and Safety of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy Tegacorat - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Not yet recruiting | Grünenthal GmbH | 36 | 2026-11-30 | 2026-11-17 |
| Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) ENTR-601-44, ENTR-601-45 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Not yet recruiting | Entrada Therapeutics, Inc. | 80 | 2026-08-01 | 2026-07-02 |
| An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy BMN 351 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Enrolling by invitation | BioMarin Pharmaceutical | 18 | 2026-04-20 | 2026-07-24 |
| An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 SAT-3247 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Recruiting | Satellos Bioscience, Inc. | 30 | 2025-09-25 | 2026-11-19 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 ENTR-601-45, ENTR-601-45 - matching placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Entrada Therapeutics, Inc. | 24 | 2025-08-30 | 2026-08-13 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 ENTR-601-44, ENTR-601-44 - matching placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Entrada Therapeutics, Inc. | 24 | 2025-06-30 | 2026-08-13 |
| A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment IV infusion, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Withdrawn | PepGen Inc | 2024-12-17 | 2025-06-24 | |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping DYNE-251, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Active not recruiting | Dyne Therapeutics | 86 | 2022-08-12 | 2026-08-11 |
| Extension Study of NS-089/NCNP-02 in DMD NS-089/NCNP-02 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Active not recruiting | Nippon Shinyaku Co., Ltd. | 6 | 2021-06-23 | 2025-07-20 |
| Twice Weekly Steroids and Exercise as Therapy for DMD Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | University of Florida | 21 | 2020-07-30 | 2026-03-13 |
| Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy eteplirsen - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 33 | 2015-06-30 | 2021-01-25 |
| A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Prednisone, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Withdrawn | Ann & Robert H Lurie Children's Hospital of Chicago | 2014-11-01 | 2015-02-18 | |
| A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Givinostat - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Completed | Italfarmaco | 20 | 2013-04-01 | 2023-11-07 |
| Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy AVI-4658 (Eteplirsen) - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | Sarepta Therapeutics, Inc. | 12 | 2012-02-27 | 2020-03-30 |
| Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy idebenone, placebo - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | Santhera Pharmaceuticals | 21 | 2005-10-01 | 2011-08-01 |
Muscular Dystrophy, Duchenne (16) · Muscular Dystrophies (2) · Neuromuscular Diseases (1) · Obesity (1) · Rare Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (16) · Genetic Diseases, X-Linked (16) · Muscular Diseases (16) · Muscular Disorders, Atrophic (16) · Musculoskeletal Diseases (16) · Nervous System Diseases (16) · Neuromuscular Diseases (15) · Muscular Dystrophies (14) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Disease Attributes (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1)
Prednisone (2) · eteplirsen (2) · Glucocorticoids (1) · Infusions, Intravenous (1) · givinostat (1) · givinostat hydrochloride (1) · idebenone (1) · semaglutide (1)
Entrada Therapeutics, Inc. (3) · Sarepta Therapeutics, Inc. (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · BioMarin Pharmaceutical (1) · Dyne Therapeutics (1) · Grünenthal GmbH (1) · Italfarmaco (1) · Nippon Shinyaku Co., Ltd. (1) · PepGen Inc (1) · Santhera Pharmaceuticals (1) · Satellos Bioscience, Inc. (1) · University of Florida (1) · Vanderbilt University Medical Center (1)
United States (7) · Italy (6) · Belgium (5) · Spain (5) · United Kingdom (5) · Netherlands (3) · Australia (2) · Canada (1) · Ireland (1) · Japan (1) · South Korea (1) · Turkey (Türkiye) (1)
Enrico Bertini, MD (1) · Gunnar Buyse, MD PhD (1) · Nancy Kuntz, MD (1) · Tanja Taivassalo, MD (1)
PMID 21435876, PMID 26573217, PMID 27566866
2023 (2), 2025 (1)